Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections

Area of Science:

• Medical Mycology
• Infectious Diseases
• Public Health

Background:

• Mucormycosis is a severe invasive fungal infection caused by Mucorales moulds, designated a high-priority pathogen group by the WHO.
• Increasing incidence and high mortality rates associated with current antifungal therapies highlight an urgent need for improved management strategies.
• COVID-19 has emerged as a significant new risk factor, alongside traditional predispositions like diabetes mellitus and immune compromise.

Purpose of the Study:

• To address the limitations of current diagnostic methods for mucormycosis, which suffer from inadequate sensitivity, specificity, and accessibility.
• To underscore the necessity for robust epidemiological surveillance to understand disease burden and identify at-risk populations.
• To highlight the potential of emerging diagnostic and therapeutic strategies in combating this deadly infection.

Main Methods:

• Review of current literature on mucormycosis epidemiology, diagnostics, and therapeutics.
• Analysis of the impact of risk factors including diabetes mellitus, immune compromise, and COVID-19.
• Evaluation of emerging diagnostic techniques (serological, molecular) and antifungal agents.

Main Results:

• Current diagnostic tools for mucormycosis lack sufficient accuracy and timely availability.
• COVID-19 is a newly identified significant risk factor contributing to mucormycosis incidence.
• Emerging diagnostic methods and novel antifungal agents show promise but require further validation and equitable access.

Conclusions:

• There is a critical need for enhanced epidemiological surveillance of mucormycosis.
• Advancements in diagnostic sensitivity, specificity, and accessibility are paramount for timely treatment initiation.
• Equitable access to novel antifungal therapies is essential to reduce the high mortality associated with mucormycosis.